{"id":1230,"date":"2022-11-28T12:34:10","date_gmt":"2022-11-28T12:34:10","guid":{"rendered":"https:\/\/www.fertitheralabs.gr\/?page_id=1230"},"modified":"2025-09-19T11:07:28","modified_gmt":"2025-09-19T11:07:28","slug":"male-and-female-infertility","status":"publish","type":"page","link":"https:\/\/www.fertitheralabs.gr\/en\/male-and-female-infertility\/","title":{"rendered":"Male and Female Infertility"},"content":{"rendered":"
\n
\n\t\t\"\"\n\t<\/div>\n\n<\/div><\/div><\/div><\/div><\/div>
\n\t\t\t\t\t\t\t

\n\t\t\t\t\t\tMale and Female Infertility\t\t\t\t\t\t<\/h1>\n\t\t\t\t\t\t<\/div>\n<\/div><\/div>
\t
\n\t\t\t
\n\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\tOverview of Male and Female Infertility\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t
\n\t\t\t\t
\n\t\t\t\t\tAccording to WHO, infertility is a disease of the male or female reproductive system defined by the failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse.\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t
\n\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\tEpidemiology\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Infertility affects millions of people of reproductive age worldwide \u2013 and has an impact on their families and communities. Estimates suggest that between 48 million couples and 186 million individuals live with infertility globally. (2, 3, 4)<\/p>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t

\n\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\tPathophysiology and causes of infertility\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

In the male reproductive system, infertility is most commonly caused by problems in the ejection of semen (1), absence or low levels of sperm, or abnormal shape (morphology) and movement (motility) of the sperm.\nIn the female reproductive system, infertility may be caused by a range of abnormalities of the ovaries, uterus, fallopian tubes, and the endocrine system, among others.\nInfertility can be primary or secondary. Primary infertility is when a pregnancy has never been achieved by a person, and secondary infertility is when at least one prior pregnancy has been achieved..\n<\/p>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t<\/div>\n\n<\/div><\/div><\/div><\/div><\/div>

\n
\n\t\t\"\"\n\t<\/div>\n\n<\/div><\/div>
\n\t
\n\t\t\t\n\t\t\t
\n\t\t\t\t\t\t\t\tQ10\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\n\t\t\t
\n\t\t\t\t\t\t\t\tA-lipoic acid\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\n\t\t\t
\n\t\t\t\t\t\t\t\tPQQ\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t<\/div>\n\n\t
\n\t\t\t
\n\t\t\t\n\t\t\t\t
\n
\n

Q10<\/h1>\n

\"Axitol<\/p>\n<\/div>\n

\n

Coenzyme Q10 (CoQ10)\u2014an essential cofactor for energy production with major antioxidant properties\u2014is commonly used to support spermatogenesis in idiopathic male infertility. This systematic review aims to elucidate the usefulness of CoQ10 supplementation in the treatment of male infertility, particularly with regard to semen quality assessed by conventional and advanced methods, and pregnancy rates. All studies report a beneficial effect of CoQ10 supplementation on semen parameters, although randomized controlled trials are a minority. Moreover, the optimal dosage of CoQ10 or how it can be combined with other antioxidant molecules to maximize its effect is unknown. However, CoQ10 is still one of the most promising molecules to treat idiopathic male infertility.<\/p>\n

Antioxidants (Basel). 2021 Jun; 10(6): 874. Published online 2021 May 30. doi: 10.3390\/antiox10060874<\/p>\n

Management of women with reduced ovarian reserve or poor ovarian response (POR) to stimulation is one of the major challenges in reproductive medicine. This prospective, randomized controlled study included 186 consecutive patients with POR stratified according to the POSEIDON classification group 3 (age\u2009<\u200935, poor ovarian reserve parameters). The participants were randomized to the CoQ10 pre-treatment for 60 days preceding IVF-ICSI cycle or no pre-treatment. The number of high quality embryos was a primary outcome measure. CoQ10 pretreatment resulted in significantly lower gonadotrophin requirements and higher peak E2 levels. Women in CoQ10 group had increased number of retrieved oocytes (4, IQR 2\u20135), higher fertilization rate (67.49%) and more high-quality embryos (1, IQR 0\u20132); p\u2009<\u20090.05. Significantly less women treated with CoQ10 had cancelled embryo transfer because of poor embryo development than controls (8.33% vs. 22.89%, p\u2009=\u20090.04) and more women from treatment group had available cryopreserved embryos (18.42% vs. 4.3%, p\u2009=\u20090.012). The clinical pregnancy and live birth rates per embryo transfer and per one complete stimulation cycle tended to be higher in CoQ10 group. Pretreatment with CoQ10 improves ovarian response to stimulation and embryological parameters in young women with poor ovarian reserve in IVF-ICSI cycles.<\/p>\n

Reprod Biol Endocrinol. 2018; 16: 29. Published online 2018 Mar 27. doi: 10.1186\/s12958-018-0343-0<\/p>\n<\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t

\n\t\t\t\n\t\t\t\t
\n
\n

A-lipoic acid<\/h1>\n

\"Axitol<\/p>\n<\/div>\n

\n

Daily supplementation with ALA improved total motility and progressive motility of the spermatozoa. In the ALA-treated group, sperm motility and progressive motility increased significantly, similarly, the mean percentage of sperm vitality demonstrated a significant increase among the ALA treated group (p\u2009<\u20090.001). Analysis revealed a statistically significant increase in semen volume and sperm concentration in the ALA supplemented group, while abnormal morphology decreased significantly (p\u2009<\u20090.001). ALA supplementation significantly improved sperm parameters and functional tests in group A patients. ALA supplementation in patients with idiopathic asthenozoospermic thus enhanced sperm quality and viability<\/p>\n

Human Fertility , Published online: 13 Jan 2022 https:\/\/doi.org\/10.1080\/14647273.2021.2025271<\/p>\n

The available literature demonstrates the positive effects of ALA in multiple processes from oocyte maturation (0.87 \u00b1 0.9% of oocyte in MII vs 0.81 \u00b1 3.9%; p \u2009< .05) to fertilization, embryo development (57.7% vs 75.7% grade 1 embryo; p \u2009< .05) and reproductive outcomes. Its regular administration both in sub-fertile women and men shows to reduce pelvic pain in endometriosis ( p \u2009< .05), regularize menstrual flow and metabolic disorders ( p \u2009< .01) and improve sperm quality ( p \u2009< .001). ALA represents a promising new molecule in the field of couple infertility.<\/p>\n

Gynecological Endocrinology Volume 37, 2021 - Issue 6, https:\/\/doi.org\/10.1080\/09513590.2020.1843619<\/p>\n

This study included 101 consecutive IVF\/ICSI cycles in 101 infertile patients over 37 years who were given lipoic acid at a dose of 200mg twice a day orally for 60-90 days before and during COS period (study group, n=53) or were not given lipoic acid (control group, n=48) in our center between March 2015 and June 2016. The expression of PGC-1alpha mRNA in granulosa cells was analyzed by realtime RT-PCR. The numbers of mature oocytes, fertilized oocytes and grade I or II embryos were significantly higher in the study (p < 0.001, p < 0.001, p = 0.003, respectively). Relative amount of PGC-1alpha mRNA in the ganulosa cells was significantly higher in the study group of 8.45 \u00b1 3.84 compared with 3.04 \u00b1 1.98 in the control group (p < 0.001). Clinical pregnancy rate seemed to be higher in the study. The supplementation of lipoic acid of 200mg twice a day for 60-90 days increases the numbers of mature oocytes and good quality embryos and PGC-1alpha gene expression in granulosa cells in aging women undergoing IVF.<\/p>\n

Fertility and Sterility, VOLUME 108, ISSUE 3, SUPPLEMENT , E228, SEPTEMBER 01, 2017 DOI: https:\/\/doi.org\/10.1016\/j.fertnstert.2017.07.689<\/p>\n<\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t

\n\t\t\t\n\t\t\t\t

Content coming soon<\/p>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div>

\t\t\t

** All data above are published as clinical trials and do not refer to EFSA claims. This means that they do not intend to be medical or therapeutical advice.<\/p>\n<\/div>\n\t\t<\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Male and Female Infertility According to WHO, infertility is a disease of the male or female reproductive system defined by the failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse.<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"slim_seo":{"title":"Male and Female Infertility - Fertithera Labs","description":"Male and Female Infertility According to WHO, infertility is a disease of the male or female reproductive system defined by the failure to achieve a pregnancy a"},"footnotes":""},"class_list":{"0":"post-1230","1":"page","2":"type-page","3":"status-publish","5":"clearfix","6":"article"},"_links":{"self":[{"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/pages\/1230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/comments?post=1230"}],"version-history":[{"count":30,"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/pages\/1230\/revisions"}],"predecessor-version":[{"id":2254,"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/pages\/1230\/revisions\/2254"}],"wp:attachment":[{"href":"https:\/\/www.fertitheralabs.gr\/en\/wp-json\/wp\/v2\/media?parent=1230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}